In 2002, Armstrong et al. [67] showed that ALL with translocations involving the KMT2A gene (previously known as MLL) presented a unique gene expression profile, different from ALL and AML without KMT2A abnormalities. This evidence concerns the gene KMT2A and acute myeloid leukemia.